Bis-001 Er
Epilepsy, Complex Partial
Supernus Pharmaceuticals, Inc.Phase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Epilepsy, Complex Partial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pregabalin Northeast Regional Epilepsy Group | Phase 4 | BBB |
Carisbamate SK Life Science, Inc. | Phase 3 | BB |
Rwj-333369 SK Life Science, Inc. | Phase 3 | BB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Phase 4 | BB |
Zonisamide Eisai Inc. | Phase 3 | B |
Diazepam Pfizer | Phase 3 | B |
Ganaxolone Marinus Pharmaceuticals | Phase 2 | B |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →